Belite Bio (BLTE) Net Income towards Common Stockholders (2022 - 2026)
Belite Bio (BLTE) recorded quarterly Net Income towards Common Stockholders of -$26.9 million in Q1 2026, up 99.89% quarter-over-quarter from -$25.3 billion in Q4 2025, and down 88.68% on a YoY basis from -$238.0 million in Q1 2025.
Belite Bio (BLTE) Net Income towards Common Stockholders (2022 - 2026) Analysis & Trends
Belite Bio's Net Income towards Common Stockholders history runs 5 years deep, the most recent figure standing at -$26.9 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 88.68% year-over-year to -$26.9 million; the TTM figure through Mar 2026 stood at -$63.4 billion (down 124.04% YoY), while the FY2025 annual figure was -$75.0 million, down 107.61% from the prior year.
- Net Income towards Common Stockholders was -$26.9 million for Q1 2026 at Belite Bio, up from -$25.3 billion in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$6.8 million in Q4 2022 to a low of -$25.3 billion in Q4 2025.
- Historically, Net Income towards Common Stockholders has averaged -$7.4 billion across 5 years, with a median of -$6.9 billion in 2023.
- The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders plunged 144392.13% in 2024, then jumped 99.82% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$6.8 million in 2022, then declined by 3.05% to -$7.0 million in 2023, then slumped by 144392.13% to -$10.1 billion in 2024, then sank by 150.73% to -$25.3 billion in 2025, then jumped by 99.89% to -$26.9 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$26.9 million (Q1 2026), -$25.3 billion (Q4 2025), and -$21.7 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Regeneron Pharmaceuticals | 63.59 Bn | 54.83 Bn | 3.31 Bn | 727.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.94 Mn |
| Dec 31, 2025 | -25.32 Bn |
| Sep 30, 2025 | -21.69 Bn |
| Jun 30, 2025 | -16.32 Bn |
| Mar 31, 2025 | -14.28 Mn |
| Dec 31, 2024 | -10.10 Bn |
| Sep 30, 2024 | -8.67 Bn |
| Jun 30, 2024 | -9.49 Bn |
| Mar 31, 2024 | -7.87 Bn |
| Dec 31, 2023 | -6.99 Mn |
| Sep 30, 2023 | -10.94 Mn |
| Jun 30, 2023 | -6.81 Bn |
| Mar 31, 2023 | -6.90 Bn |
| Dec 31, 2022 | -6.78 Mn |
| Sep 30, 2022 | -2.40 Bn |
| Jun 30, 2022 | -2.39 Bn |